Therapeutic Symposium
Th is yea r's Therapeutic Sympos ium focused on th ẽ Ii nica l pharmacology o f H j-receptor antagon ist drugs 10 the treatment of gastrointestinal disease. James King, M.D. , Gastroenterology Associates, Inc., Can ton, OH, opened the sessio n with an overview of the pathogenesis and clinical classificati on of gas tro intestina l diseases associated with acid hyper secretion. J. Robert Powell, Pharm.D., Universit y of North Carolina, Chapel Hill, wh~served as moderator of thi s session , presented the basic pharmacology and pharmacokinetics of Hj-antagoni sts. Ranitidine's lack o f reported endocrine effects t~u s far , lack of effect on hep atic enzyme system s, higher pot~n~y, and higher renal clear ance, as compared with cimetidine, were explained and discussed . Fred N. Eshelman , Pharm .D ., Gla xo , Inc. , Research Tri an gle Pa rk , N~,. presented a clinical co ntrast of the two drugs, summa n zing recent clin ical studies on the sho rt-ter m treatment of acti ve duodenal ulcer ; one-year recurrence rat e of gastric ulcer , with maintenance therapy; a nd management of gastroesophageal reflux. Studies thus far suggest that both dru gs are equal in healing duodenal ulcers at four weeks and gastric ulcer s at six weeks. Prelim inary evidence for on e-year maintenance shows th e recurrence rate o f duodenal ulcers to be approx ima tely 30 percent with ranitidine a nd 50 percent with cimet idine . Both drugs provide sympto matic relief of gastroesophageal reflux, but no evidence of endoscopi c change. Headache is reported more frequently with ranitidine ( -3 percent); it is too early to know whether ranitidine causes confusion in the elderly, as cimetidine can.
Aft er these detailed discussions and compa rison of the two dru gs, Joseph Gri ffin, Jr. , M.D. , Medical C o ll eg e of Ge orgi a , Augusta, put the dru gs in perspective by discussing th e overall managem ent o f pepti c ulcer disease. Gri ffin noted that , in cos t, H j-antagoni st dru gs are equal to o r lower than intensive ant -J es eph LriHin. J r. •~1.D _ . d ivcus-c th e acid therapy and are rrcau n cn t o f pe ptic ulcer s. more reliable . The symposium ended with an excellent discussion of less co mmo n , but more difficult to treat gastric hypersecretory states, presented by Rob ert J ensen, M.D., Digestive Disea ses Branch, National Instit utes of Health (NIH), Washington, DC. Jensen stated that the NIH ha s shown that long-term medic al treatment of these disorders is adeq uate, and ga strectomy is rarel y necessary. In contrast to their use in du odenal ulcer treatment, H j-ant agon ists often must be given in megadoses to control gas tric hypersecret ion . Some pati ent s require 3-12 g/d of cimet idine or as much as 6 g/ d of ranitidine. With high-dose cimetidine, impotence and gynecom astia ha ve been seen in about 50 percent of male s; when therapy was changed to ranitidine , the endocrine effects disappeared. No cent ral nervous system effect s were seen with either dru g. So-called i m e t i d i n e resistance was de fined by Jensen as merely ina deq uate dosage. Therap y with either drug is a ided by the addition of ant ichol inerg ic agent s.
Second Plenary Session
Will the third-generation cephalospo rins replace aminoglycosides in th e tre atment of gram-negative infections? This was the qu estion posed for the pointcounterpoint session. Angela M. Ristuccia, Pharm.D ., Pharm .D., Likoff Cardiovascular Institute, Philadelphia, discussed factors affecting the efficacy of NSAIDs, and Ronald P. 
Pharmacy Industry Forum
Sixteen scientific exhibits were displayed at the Second Annual Pharmacy Industry Forum . These exhibits provided clinical information about pharmaceutical products and services, provided a medium for exchange of new research findings and ideas, and allowed a Roberl M. Elenbaas, Pha rm .D ..
A CCP secretary. ser ves as moderaforum for developing relation lor for the co ntributed papers ships between ACCP members scw ion. and industry colleagues. Exhibitors included professional services directors , scientific training directors, research managers, and senior product managers. This new concept for pharmacy meetings achieved its goal of providing scientists from industry and the ACCP an opportunity to discuss mutual interests. and Drug Administra-_ tion, Washington, DC, who discussed the role of the clinical pharmacist as an investigator in human drug trials (see ACCP News, DICP 1983; 17:675-6) . The final presentation of that session was a discussion 0 f the Alan S. Kaplan, M .D .. Ph.D .. comments on the American Medical As-role o f clinica l pharmacists in dru g tria ls. sociation's drug information data base . Ross Weaver, Pharm.D., AMA, Chicago, described program capabilities of the data base and opportunities for clinical pharmacists.
Contributed Papers
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N ew Officers
At the annual banquet , the 1983-84 officers a nd regent s were installed . They a re : Glen L. 
Therapeutic Frontiers Lecture A ward
Gerhard Levy, Pharm.D ., received the ACCP 's highest honor, and his presentation was a highlight of the meeting. Although Levy 's outstanding contributions have been recognized with many awards and honorary degrees, the Therapeutic Frontiers Lecture Award is un ique in that it recognized him for his research plan s that will unfold o ver the next decade. Levy' s presentation , "The Other Side of Clinical Pharmacokinetics: Relationship Between Drug Concentration and Pharmacologic Effect," provid ed a glimpse of the future in te rm s of needs and direction.
